The evaluation of lipoprotein changes during gemfibrozil treatment.
During treatment with gemfibrozil, 1200 mg daily, total serum triglyceride levels were reduced in 7 of the 11 patients, owing chiefly to a fall in VLDL triglyceride levels. Total serum cholesterol responded variably, falling in a majority of patients with hypercholesterolaemia. High density lipoprotein cholesterol rose during treatment in patients who had either hypertriglyceridaemia or hypercholesterolaemia.
D002784:Cholesterol / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000009:adverse effects / Q000627:therapeutic use*; D014992:Xylenes / Q000009:adverse effects / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D008074:Lipoproteins; D014280:Triglycerides; D014631:Valerates; D014992:Xylenes; D002784:Cholesterol